ORASURE TECHNOLOGIES INC Form 8-K March 18, 2005

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 15, 2005

OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction

of Incorporation)

001-16537 (Commission File Number) 36-4370966 (I.R.S. Employer

Identification No.)

220 East First Street

18015-1360

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

Bethlehem, Pennsylvania (Address of Principal Executive Offices)

(Zip Code)

Registrant s telephone number, including area code: 610-882-1820

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry Into a Material Definitive Agreement

OraSure Technologies, Inc. (the Company) and Koninklijke Utermöhlen N.V. (Utermöhlen) are parties to a Production Agreement, dated June 8, 1998, as amended (the Production Agreement), pursuant to which Utermöhlen supplies to the Company its Histofree **2earnd** Freeze Off cryosurgical products. On March 15, 2005, the Company and Utermöhlen entered into Amendment No. 3 to Production Agreement, dated as of March 9, 2005 (the Amendment), which extends the term of the Production Agreement with respect to the Histofree **2eproducts**, establishes certain minimum purchase commitments for the Company, adjusts the purchase price of the Freeze Off product and provides for certain adjustments to the purchase price of the Histofreeze[®] products in the event of fluctuations in the Euro/U.S. Dollar exchange rate.

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: March 18, 2005

By: /s/ Jack E. Jerrett

Jack E. Jerrett Senior Vice President, General Counsel and Secretary

3